- Companies
- IM Cannabis
IM Cannabis Valuation Multiples
IM Cannabis is valued at $4M as of September 2026, a 0.3x revenue multiple. In the last fiscal year, IM Cannabis revenue was $39M and IM Cannabis EBITDA was ($5M).
IM Cannabis Overview
About IM Cannabis
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
Founded
1980
HQ
Employees
55
Website
Financials (Last FY)
EV
$13M
Valuation Multiples
Start free trialIM Cannabis Financials
IM Cannabis reported last fiscal year revenue of $39M and negative EBITDA of ($5M).
In the same fiscal year, IM Cannabis generated $7M in gross profit, ($5M) in EBITDA losses, and had net loss of ($8M).
IM Cannabis P&L
In the most recent fiscal year, IM Cannabis reported revenue of $39M and EBITDA of ($5M).
IM Cannabis is unprofitable as of last fiscal year, with gross margin of 18%, EBITDA margin of (13%), and net margin of (21%).
Financial data powered by Morningstar, Inc.
IM Cannabis Stock Performance
IM Cannabis has current market cap of $4M, and enterprise value of $13M.
Market Cap Evolution
IM Cannabis' stock price is $2.46.
IM Cannabis share price decreased by 18.8% in the last 30 days.
IM Cannabis has an EPS (earnings per share) of $-4.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $4M | -13.4% | -18.8% | - | - | $-4.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIM Cannabis Valuation Multiples
IM Cannabis trades at 0.3x EV/Revenue multiple, and (2.6x) EV/EBITDA.
IM Cannabis Financial Valuation Multiples
As of September 29, 2026, IM Cannabis has market cap of $4M and EV of $13M.
IM Cannabis has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IM Cannabis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IM Cannabis Margins & Growth Rates
In the most recent fiscal year, IM Cannabis reported gross margin of 18%, EBITDA margin of (13%), and net margin of (21%).
IM Cannabis Margins
IM Cannabis Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IM Cannabis Operational KPIs
IM Cannabis' revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
IM Cannabis Competitors
IM Cannabis competitors include Weed, Panacea Life Sciences, Ubiquitech Software, Strainsforpains, Elixinol Wellness, PsyRx CNS Bio-Tech, CordovaCann, Dogecoin Cash, SynBiotic and Neon Bloom.
Most IM Cannabis public comparables operate across Cannabis, CannaTech and ViceTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | ($1M) | - | - | (3.7x) | - | |||
| $2M | ($5M) | 2.1x | - | (1.1x) | - | |||
| - | - | - | - | - | - | |||
| - | - | - | - | - | - | |||
| $11M | ($3M) | 0.4x | - | (1.4x) | - | |||
| - | - | - | - | - | - | |||
| $10M | ($578K) | 0.6x | - | (10.2x) | - | |||
| $739K | ($10M) | 3.8x | - | (0.3x) | - | |||
This data is available for Pro users. Sign up to see all IM Cannabis competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by IM Cannabis
IM Cannabis has acquired 5 companies to date.
Last acquisition by IM Cannabis was on September 23rd 2026. IM Cannabis acquired Space Defense Innovations for undisclosed valuation.
Latest Acquisitions by IM Cannabis
| Description | Space Defense Innovations is a technology company active in space and defense sectors. | Blackaxe Technologies is a Polish supplier of defense and security technologies including satellite-based intelligence and counter-drone systems through partnerships with global technology leaders. | Oranim Pharm is a Haifa-based pharmacy chain in Israel distributing medical cannabis products including oils, flowers, and edibles prescribed for pain management and other conditions. The firm operates multiple outlets and online services compliant with Israeli health regulations. | MYM Nutraceuticals is a Vancouver-based producer of organic medicinal cannabis oils, capsules, and topicals under Health Canada licenses. Its Quebec facilities span 1.5 million square feet for cultivation and extraction, yielding 20,000 kg annually. Products distribute to licensed retailers in Canada via partnerships with Aurora Cannabis. Established in 2016, MYM focuses on CBD-dominant formulations for wellness markets. | |
| HQ Country | - | ||||
| HQ City | - | - | Jerusalem | Vancouver | |
| Deal Date | 23 Sep 2026 | 16 Mar 2026 | 30 Mar 2022 | 1 Apr 2021 | |
| Valuation | undisclosed | undisclosed | $9M | $87M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all IM Cannabis acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IM Cannabis
| When was IM Cannabis founded? | IM Cannabis was founded in 1980. |
| Where is IM Cannabis headquartered? | IM Cannabis is headquartered in Israel. |
| How many employees does IM Cannabis have? | As of today, IM Cannabis has over 55 employees. |
| Is IM Cannabis publicly listed? | Yes, IM Cannabis is a public company listed on Nasdaq. |
| What is the stock symbol of IM Cannabis? | IM Cannabis trades under IMCC ticker. |
| When did IM Cannabis go public? | IM Cannabis went public in 1997. |
| Who are competitors of IM Cannabis? | IM Cannabis main competitors include Weed, Panacea Life Sciences, Ubiquitech Software, Strainsforpains, Elixinol Wellness, PsyRx CNS Bio-Tech, CordovaCann, Dogecoin Cash, SynBiotic, Neon Bloom. |
| What is the current market cap of IM Cannabis? | IM Cannabis' current market cap is $4M. |
| What is the current revenue of IM Cannabis? | IM Cannabis' last fiscal year revenue is $39M. |
| What is the current EV/Revenue multiple of IM Cannabis? | Current revenue multiple of IM Cannabis is 0.3x. |
| Is IM Cannabis profitable? | No, IM Cannabis is not profitable. |
| How many companies IM Cannabis has acquired to date? | As of September 2026, IM Cannabis has acquired 5 companies. |
| What was the largest acquisition by IM Cannabis? | $87M acquisition of MYM Nutraceuticals on 1st April 2021 was the largest M&A IM Cannabis has done to date. |
| What companies IM Cannabis acquired? | IM Cannabis acquired MYM Nutraceuticals, Trichome Financial, Oranim Pharm, Space Defense Innovations, and Blackaxe Technologies. |
| In how many companies IM Cannabis has invested to date? | IM Cannabis hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to IM Cannabis
Lists including IM Cannabis
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




